Here's an post layout for the upcoming trial(s) I hope is useful and concise enough to fit in all the relevant info. What I also find interesting is how we literally have the commercial pipelines available through CannVaLate as distributors, the product already created if successfully tested and the relevant licenses and approvals for I think all of the products that are going to be tested. Going to try and make a clean outline.
The better plays in this space include the likes of AGH which has bagged 6 times so far and still continuing on a beautiful uptrend with their partnership with CannVaLate as distributors too, albeit without CannVaLate having a stake in them which they will have with IHL. Althea has proven to have patients, and is growing their patient base internationally. With this in mind, remember they are loss making and immensely loss making too unlike IHL which produces revenue and is decreasing costs every quarter. Comparisons can also be drawn to BOT, but won't discuss further on this post.
The path to commercialisation of our products is so clean, I will post below what we know so far for our four upcoming trials. Perionditis - AXIM already supplier for IHL as per binding agreement, product ready to go. AXIM compensated by shares in Impression as per the latest 3B. Market by 700M by 2023. Not the largest market there is, but this is only 1 out of 4 trials with sleep apnea being the largest by far. This is still decent enough that a piece of the pie would be very substantial, especially for a 40M capped company.
Concussion - Can't find anything specific RE the Concussion Oils besides that they are using synthetic, similar to BOT. Looks like they will most likely use AXIM as supplier, especially if the first trial goes well. Product will be sourced likely through AXIM, no doubt announcement will be released in the near future when they finalize this.
Sleep Apnea - The largest potential market of all worth 8.15B in 2018, Sleep Apnea and Dronabinol. Myoderm North America will be supplying the goods.
Joint Dysfunction - Again, similar to concussion can't find anything specific RE Oils, most likely sourced from a Canadian manufacturer or from AXIM as outlined earlier.
Generic Cannabis Oils - This will obviously assist in boosting revenue, probably not much else. I don't know who the Canadian Manufacturer is, and that news was from Dec 2018. More likely that there will be updates to come in the near future regarding this, but this is the least important of all the potential plays listed here for the MedCann side of the biz.
Finally, would like to leave some thoughts from Dr Agarwal of CannVaLate regarding their partnership with Impression, remember they are also partnered with 160M capped Althea (AGH) and are partly owned by Rich Lister Nick Bell.
This post is partly for myself to refer to any time I need an overall quick one post refresher of the scope of the company's operations so far, and a reminder that practically all products are sourced and supplied, ready to go for the trials. Upon success of the trials, they will literally be pushed to commercialization if possible, IHL has the relevant licenses to sell cannabinoid products in Australia and can apply for them overseas with ease, especially if successful here. Also, using CannVaLate as distributor is absolutely massive, not going to ramble on about anything more but this should be enough for one post. Hope this helps everyone! Oh yeah, before I forget 40 Million MC by the way. DYOR. -Exalted
